Changes in oxidative stress markers in patients with schizophrenia: The effect of antipsychotic drugs

The aim of this study was to investigate the serum levels or activities of oxidative stress markers in patients with schizophrenia in acute phase and evaluate the changes in superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione (GSH) and thiobarbituric acid-reactive substances (TBARS) after treatment. We consecutively enrolled 41 patients with schizophrenia in acute phase, and 27 patients were followed up with a 4-week antipsychotic treatment. Serum oxidative stress markers were measured with assay kits. We found that Positive and Negative Syndrome Scale (PANSS) total scores were significantly negatively correlated with serum GPx activity and GSH levels and positively correlated with serum SOD activity in patients with schizophrenia in acute phase. In addition, serum GPx activity had a positive correlation with GSH levels and negative correlation with SOD activity. We also found that serum SOD activity was significantly negatively correlated with TBARS levels in patients in acute phase. Furthermore, we found significantly increased changes only in GPx activity in female patients receiving the 4-week treatment (P=0.006). In conclusion, our results suggest that SOD, GPX and GSH might be indicators of schizophrenia severity in acute phase. Furthermore, antipsychotic drugs might affect serum GPx activity in female patients receiving the 4-week treatment.

[1]  J. Pendlebury,et al.  A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry? , 2010, Annals of clinical biochemistry.

[2]  Sandhya Mishra,et al.  Evaluation of antioxidant deficit in schizophrenia , 2008, Indian journal of psychiatry.

[3]  Faris A. Ahmed,et al.  Potential Effect of Olanzapine on Total Antioxidant Status and Lipid Peroxidation in Schizophrenic Patients , 2009, Neuropsychobiology.

[4]  Alin Ciobica,et al.  Oxidative stress in schizophrenia - focusing on the main markers. , 2011, Psychiatria Danubina.

[5]  J. Hirrlinger,et al.  Peroxide detoxification by brain cells , 2005, Journal of neuroscience research.

[6]  T. Woo,et al.  Oxidative stress in schizophrenia: An integrated approach , 2011, Neuroscience & Biobehavioral Reviews.

[7]  L. Qi,et al.  Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics , 2009, Psychopharmacology.

[8]  D. Janero,et al.  Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. , 1990, Free radical biology & medicine.

[9]  M. Cuénod,et al.  Redox dysregulation, neurodevelopment, and schizophrenia , 2009, Current Opinion in Neurobiology.

[10]  V. Parikh,et al.  Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. , 2003, Journal of psychiatric research.

[11]  T. Kosten,et al.  Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia , 2012, Neuropharmacology.

[12]  Y. Ishii,et al.  Redox Regulation of Cell Growth and Cell Death , 2003, Biological chemistry.

[13]  David R. Jones,et al.  Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  S. Mukherjee,et al.  Impaired antioxidant defense at the onset of psychosis , 1996, Schizophrenia Research.

[15]  Ganesh Dakhale,et al.  Oxidative Damage and Schizophrenia: The Potential Benefit by Atypical Antipsychotics , 2004, Neuropsychobiology.

[16]  S. Grignon,et al.  Assessment of malondialdehyde levels in schizophrenia: A meta-analysis and some methodological considerations , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  A. Sarandol,et al.  Oxidative–antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[18]  E R James,et al.  Superoxide dismutase. , 1994, Parasitology today.

[19]  M. Keshavan,et al.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. , 2011, Antioxidants & redox signaling.

[20]  S. Yamawaki,et al.  Protective Action of Neurotrophic Factors and Estrogen against Oxidative Stress-Mediated Neurodegeneration , 2011, Journal of toxicology.

[21]  A. Ciobica,et al.  Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics , 2010, Neuroscience Letters.

[22]  F. Kapczinski,et al.  Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  E. Wills.  Mechanisms of lipid peroxide formation in animal tissues. , 1966, The Biochemical journal.

[24]  Jeffrey K. Yao,et al.  Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. , 2011, Antioxidants & redox signaling.

[25]  A. Kerkeni,et al.  Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  M. First,et al.  User's guide for the structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version , 1997 .

[27]  J. Quevedo,et al.  Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain , 2004, Neuroscience Letters.

[28]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[29]  G. Konat.  H2O2-induced higher order chromatin degradation: A novel mechanism of oxidative genotoxicity , 2003, Journal of Biosciences.

[30]  Etelvino J. H. Bechara,et al.  Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. , 1986, Clinical chemistry.

[31]  M. Figueira,et al.  Gender-related endocrinological dysfunction and mental disorders , 2010, Current opinion in psychiatry.

[32]  David R. Jones,et al.  Correlation analysis confirms differences in antioxidant defence in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication , 2010, Psychiatry Research.

[33]  Tsu-Kung Lin,et al.  Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: Effects of antipsychotic drugs , 2010, Psychiatry Research.

[34]  Jeffrey K. Yao,et al.  An Overview of the Evidence and Its Therapeutic Implications , 2001 .

[35]  Yan Shen,et al.  Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics , 2006, Schizophrenia Research.

[36]  G. Reynolds,et al.  Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. , 2011, Pharmacogenomics.

[37]  Lewis A. Opler,et al.  Reliability and validity of the positive and negative syndrome scale for schizophrenics , 1988, Psychiatry Research.

[38]  F. Tarazi,et al.  Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. , 2002, Nitric oxide : biology and chemistry.

[39]  Michael Berk,et al.  Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  Takayuki Obata,et al.  Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study , 2008, PloS one.

[41]  P. Kochanek,et al.  Effects of post‐injury hypothermia and nerve growth factor infusion on antioxidant enzyme activity in the rat: implications for clinical therapies , 2004, Journal of neurochemistry.

[42]  T. Kosten,et al.  Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[43]  D. Berg,et al.  Redox imbalance , 2004, Cell and Tissue Research.

[44]  J. Irazusta,et al.  Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: A 12-months follow-up study , 2012, Psychiatry Research.

[45]  A Dietrich-Muszalska,et al.  Oxidative stress in blood platelets from schizophrenic patients , 2005, Platelets.

[46]  J. Ramos-Loyo,et al.  Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. , 2007, Journal of psychiatric research.

[47]  S. Mukherjee,et al.  Elevated Plasma Lipid Peroxides at the Onset of Nonaffective Psychosis , 1998, Biological Psychiatry.

[48]  A. Horton,et al.  Lipid peroxidation and mechanisms of toxicity. , 1987, Critical reviews in toxicology.

[49]  R. Głowacki,et al.  Oxidative/Nitrative Modifications of Plasma Proteins and Thiols from Patients with Schizophrenia , 2009, Neuropsychobiology.

[50]  G. Meredith,et al.  Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats , 2003, Neuropharmacology.

[51]  T. Kosten,et al.  Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[52]  D. Kammen,et al.  Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. , 1998, Journal of psychiatric research.

[53]  Abraham Nyska,et al.  Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification , 2002, Toxicologic pathology.